on Tuesday before the bell. The analysts EPS is 55 cents with sales of $14 billion. The first quarter EPS last year was 58 cents. It would be nice if ithe 58 cent EPS was matched this year. Just as important as EPS is the comapny's guidance for the remaining part of the year. There have been may times when PFE matched or exceeded EPS but the mundane guidance caused the stock price to go down on report day. I am a little concerned about the recent European market denial of PFE's rheumatoid arthritis drug which I am sure will be discussed in the earnings report on Tuesday.